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Acquired immunodeficiency syndrome
(AIDS) drug assistance programs
(ADAPs) provide access to medications for
people who lack other health coverage.  In
this article, the authors present the results
of a 1997 survey identifying how 48 States
implemented ADAPs, focusing on the num-
ber of beneficiaries, medical and financial
eligibility criteria, the administration of
waiting lists, and the coverage of drugs
including protease inhibitors.   Increased
funding for ADAPs is necessary to main-
tain this important part of the public sector
safety net for human immunodeficiency
virus (HIV) care.
INTRODUCTION
Drug therapies for the treatment of
infection with HIV and related opportunis-
tic infections are the primary weapons to
improve the quality of life and increase the
length of survival for people with HIV dis-
ease.  The combination of nucleoside anti-
retrovirals with protease inhibitors demon-
strates the greatest potential for reducing
plasma HIV and increasing CD4 cell
counts (Collier et al., 1996).  In fact, recent
studies demonstrate that these combina-
tion drug therapies slow the progression of
HIV disease (Hammer et al., 1997) and
have beneficial effects lasting for as long as
at least 1 year (Gulick et al., 1997).  In addi-
tion, AIDS researchers presenting at an
Interscience Conference on Antimicrobial
Agents and Chemotherapy in Toronto,
Canada, in September, 1997, concluded
that the three-drug therapy continues to
fight off HIV in 79 percent of the patients
treated for 2 years and that the immune
system strengthens the longer the drugs
work (Waldholz, 1997).  
Although there is limited information
about the best time to initiate therapy, the
International AIDS Society currently rec-
ommends that antiretroviral therapy be
considered for all HIV-infected individuals
with detectable plasma HIV ribonucleic
acid (Carpenter et al., 1997).  In addition,
treatment guidelines published by the
Federal Government recommend a triple-
drug regimen, with the preferred treat-
ment including at least one protease
inhibitor (Fauci et al., 1997).  Hence, there
is a growing consensus for offering treat-
ment at earlier stages of the disease with
combinations of several drugs.  
Similarly, increased knowledge and
experience with treating HIV-related
opportunistic illnesses resulted in the
development of guidelines for the preven-
tion of these infections by the U.S. Public
Health Service and the Infectious Disease
Society of America (Centers for Disease
Control and Prevention, 1997b).  The inci-
dence rates of a number of opportunistic
infections among people with HIV disease
have declined in recent years and are
being diagnosed at a later stage of HIV dis-
ease as a result of the effective use of anti-
retroviral drugs, targeted preventive thera-
py, and more comprehensive clinical 
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management of the disease (Moore and
Chaisson, 1996).  Given the use of combi-
nation drug therapies to fight HIV infection
and the use of medications to treat related
opportunistic infections, the number of
drugs needed by people with HIV disease
can be extensive, particularly for those in
later stages of the disease.
With the advent of highly active anti-
retroviral therapy and other medications,
the clinical course of HIV disease is chang-
ing in the United States.  The annual inci-
dence of HIV-related opportunistic infec-
tions declined in 1996 for the first time
(Centers for Disease Control and
Prevention, 1997a).  A study of people with
HIV disease who were at the greatest risk
for illness or death shows a dramatic
reduction in morbidity and mortality, with
these reductions in disease and death
linked to the increased use of combination
antiretroviral therapy, and the most dra-
matic reductions associated with the use of
protease inhibitors (Palella et al., 1998).
This study documented that mortality
declined from 29.4 per 100 person-years in
1995 to 8.8 per 100 person-years during
1997.  Similarly, the incidence of selected
opportunistic infections declined from 21.9
per 100 person-years in 1994 to 3.7 per 100
person-years during 1997.  
These trends suggest that access and
adherence to HIV drug regimens, particu-
larly combination antiretrovirals including
the protease inhibitors, are increasingly
important to the survival of individuals
with HIV disease.  However, these effective
medications are expensive, with combina-
tion antiretroviral therapy including pro-
tease inhibitors costing at least $12,000 per
year for each person treated (Hirschel and
Francioli, 1998).  Earlier and more inten-
sive treatment of HIV carries important
implications for State and Federal pro-
grams that assist individuals in obtaining
medications.  As more individuals with HIV
seek care, public programs are faced with
a growing demand for expensive drug-
related benefits in an environment of limit-
ed public resources.  
RYAN WHITE CARE ACT
The Ryan White Comprehensive AIDS
Resource Emergency (CARE) Act (Public
Law 101-381) was enacted in August, 1990,
to improve both the quality and availability
of care for people with HIV disease and
their families (U.S. Department of Health
and Human Services, 1993).  The original
legislation authorized:  grants to metropol-
itan areas with the largest number of AIDS
cases to help provide emergency services
(Title I);  grants to the States to improve
the quality, availability, and organization of
health and related support services (Title
II);  grants to State health departments for
AIDS early intervention services (Title III-
a) and community-based primary care
facilities (Title III-b); and grants for
research and evaluation initiatives, includ-
ing demonstration programs for pediatric
AIDS research (Title IV) (McKinney, et al.,
1993).  Title II of the CARE Act allows
States to allocate funds among any or all of
four areas to cover home-based health ser-
vices, provide medication and other treat-
ments, continue private health insurance
coverage, or fund HIV care consortia
(Health Care Financing Administration,
1995).
Federal appropriations for the CARE Act
have increased dramatically since the law’s
inception.  As Table 1 shows, total Federal
appropriations for all CARE Act programs
increased from $220.6 million in 1991 to
$1.15 billion during 1998, with more than
$1.3 billion requested in President
Clinton’s proposed budget for fiscal year
1999.  Table 1 also illustrates the sharp
increase in Federal appropriations for Title
II programs.  Federal spending on Title II
2 HEALTH CARE FINANCING REVIEW/Spring 1998/Volume 19, Number 3
increased from $87.8 million during 1991
to $543 million in 1998, with $670 million
requested in the President’s proposed bud-
get for fiscal 1999.  In addition, Table 1
shows Title II supplemental funding for the
ADAPs that began in 1996 increasing from
$52 million during that year to $285.5 mil-
lion during 1998, with $385.5 million
requested in the President’s proposed bud-
get for 1999.
Focusing on State funding for the
ADAPs, these programs may receive rev-
enues from other sources in addition to
Title II spending.  Eligible metropolitan
areas funded by Title I of the CARE Act
may allocate some of their resources to the
ADAP in their State (Health Resources and
Services Administration, 1997).  During
Federal fiscal year 1996, 35 States con-
tributed $53 million to the ADAPs in their
respective States, and 34 States allocated
more than $100 million during fiscal year
1997 (Health Resources and Services
Administration, 1997).  For example,
California contributed more than $27 mil-
lion, New York contributed more than $10
million, and Louisiana $16 million during
1997, but most States contributed less than
$1 million or nothing at all to their ADAP
during 1997 (Health Resources and
Services Administration, 1997).  Of the
total ADAP funding in the United States of
$387.9 million from all sources during fis-
cal year 1997, about $220 million (57 per-
cent) came from Title II of the CARE Act,
$41 million (11 percent) came from Title I
of the CARE Act, $101 million (26 percent)
came from State funding, and $26 million
(7 percent) came from other sources
(Health Resources and Services Admini-
stration, 1997).
Although the Ryan White legislation did
not establish income eligibility restrictions
for people to receive CARE Act services,
the law did specify that CARE Act pro-
grams must be the payer of last resort
(Health Care Financing Administration,
1995).  However, CARE Act funds can be
used  to pay for care provided to Medicaid
recipients if the State Medicaid program
does not cover a needed health service or
if a Medicaid recipient’s need for a health
HEALTH CARE FINANCING REVIEW/Spring 1998/Volume 19, Number 3 3
Table 1
Federal Appropriations for the Ryan White CARE Act, by Program: 1991-99
CARE Act Program 1991 1992 1993 1994 1995 1996 1997 1998 1999 1
(in Millions)
Total CARE Act $220.6 $279.1 $348.0 $579.4 $633.0 $757.4 $996.3 $1,150.2 $1,315.2
Title I—Emergency Relief 87.8 121.6 184.8 325.5 356.5 391.7 449.9 464.8 489.8
Title II—
HIV Care 87.8 107.6 115.3 183.9 198.1 260.8 417.0 543.0 670.0
(State ADAP) 2 0.0 0.0 0.0 0.0 0.0 (52.0) (167.0) (285.5) (385.5)
Title IIIb—Early Intervention 44.9 49.8 48.0 48.0 52.3 56.9 69.6 76.3 86.3
Title IV—Pediatric AIDS 0.0 0.0 0.0 22.0 26.0 29.0 36.0 41.0 44.0
AIDS Education
Training Centers NA NA NA NA NA 12.0 16.3 17.3 17.3
Dental Reimbursements NA NA NA NA NA 6.9 7.5 7.8 7.8
1 President's proposed budget for fiscal year 1999.
2 State ADAP spending levels (in parentheses) are a subset of spending for HIV care, and ADAP spending levels are included in HIV care 
spending levels.
NOTES:  These are Federal fiscal years. HIV is human immunodeficiency virus.  AIDS is acquired immunodeficiency syndrome.  ADAP is AIDS 
drug assistance program.
SOURCE: Office of Policy and Program Development, Health Resources and Services Administration, 1998.
service exceeds the Medicaid program’s
limits on utilization.  If a State Medicaid
program does not cover hospice care, for
example, a Medicaid recipient can receive
that service through a program funded by
the CARE Act, if available.  Similarly, if a
Medicaid recipient needs more home nurs-
ing visits then allowed by the State
Medicaid program, programs funded by
the CARE Act may pay for additional home
nursing care (Health Care Financing
Administration, 1995).
ADAPs in each State can provide access
to needed drug therapies for people who
lack other types of health insurance cover-
age. Even before the new protease
inhibitors were approved by the Food and
Drug Administration (FDA), budget con-
straints forced ADAPs in many States to
reduce the number of drugs included on
their formularies and to restrict eligibility
for program benefits, with some States
implementing waiting lists (Buchanan and
Smith, 1996).  The expense of the protease
inhibitors, when used in combination drug
therapies, will make the fiscal problems of
these ADAPs even worse.  The objective of
this article is to identify how States are
implementing ADAPs.  This research pre-
sents the results of a 1997 survey that col-
lected data on:  ADAP beneficiaries, includ-
ing financial and medical eligibility poli-
cies; changes in ADAP eligibility criteria;
the implementation of waiting lists for
ADAP coverage, with the number of people
and the length of time waiting; the use of
drug formularies, the number of drugs
covered and a summary of how new drugs
are added to the formularies; changes in
the number of drugs covered by the
ADAPs; and coverage of the protease
inhibitors by the ADAPs in each State, as
well as assessments of the impact these
medications are having on the ADAPs in
each State. 
METHODOLOGY
This survey of the State ADAPs was part
of an HIV-related project funded by a grant
from HCFA.  The survey questionnaire
included four sections:  (1) the number of
people receiving benefits, with questions
assessing changes in the number of people
covered; (2) medical and financial eligibili-
ty policies, with questions assessing
changes in financial eligibility criteria and
questions relating to the implementation of
waiting lists; (3) prescription drug cover-
age, with questions asked about the num-
ber of drugs covered, changes in the num-
ber of covered drugs, the off-label use of
drugs, and how new drugs are added to
the ADAP formulary; and (4) ADAP cover-
age of protease inhibitors and the impact
this coverage is having on the ADAP in
each State.
The survey began in early March 1997,
with four additional mailings of the ques-
tionnaire sent to States not responding at
about 6-week intervals.  The question-
naires were sent to the AIDS program
directors in the 50 States and the District of
Columbia.  The names and addresses of
these program directors were initially
obtained from the Health Resources and
Services Administration (1995).  Through
contact with these program directors, an
updated mailing list for 1997 was devel-
oped that focused on ADAP administrators
in each State (Buchanan and Smith, 1996).  
Completed questionnaires were
received from 48 States when the survey
ended in late September 1997.1 The sur-
vey responses were summarized into four
tables and mailed to the ADAPs for verifi-
cation, corrections, or updates in October
1997.  Updates and corrections received
from the ADAPs are included in the tables
presented in this article.  The survey
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1 Survey responses were not received from the ADAPs in the
District of Columbia, Iowa, and Oklahoma.
process, including verification, was com-
pleted in December 1997.
ADAP BENEFICIARIES AND 
ELIGIBILITY POLICIES
ADAP Beneficiaries
The questionnaire asked the ADAP
administrators to estimate the number of
people who received drug benefits from
the ADAP in their State during 1997, with
the responses presented in Table 2.  The
ADAPs provided prescription drug cover-
age to large numbers of people, especially
in States with a high incidence of HIV dis-
ease.  For example, the ADAP in California
provided medication coverage to an esti-
mated 20,000 people during 1997, while the
program in Florida provided drug benefits
to an estimated 7,000 people.  The ADAP in
New York provided drug coverage to more
than 10,600 people, and the ADAP in Texas
served more than 5,400 during 1997.
In addition, the questionnaire asked the
ADAP administrators to estimate how the
number of people receiving ADAP benefits
in their State during 1997 compared with
the number of people receiving these ben-
efits in 1996.  The ADAP administrators in
almost all States estimated that the number
of people receiving ADAP benefits during
1997 increased, compared with 1996,
except for Illinois, Nevada, and North
Dakota, where the ADAP administrators
estimated that the number of people
receiving benefits remained the same dur-
ing 1997, compared with 1996.2 In addi-
tion, the ADAP administrator in Alabama
estimated that the number of people
receiving ADAP benefits in that State
decreased in 1997, and the administrator
from Missouri reported that the ADAP in
that State began in late 1996, thus making
a comparison inappropriate.
The questionnaire also asked the ADAP
administrators to estimate how the number
of people expected to receive ADAP bene-
fits during 1998 compares with the number
of people receiving these benefits in 1997.
The ADAP administrators in almost all
States expect the number of people receiv-
ing medications from ADAPs to increase in
1998, compared with 1997, and ADAP
administrators expect the number of peo-
ple receiving benefits to remain the same
during 1998 in Alabama, Georgia (unless
additional funds are received), and South
Dakota.3 (The ADAP administrator from
Missouri did not answer this question and
the District of Columbia, Iowa, and
Oklahoma did not respond to the survey.)
Medical Eligibility Policies
The questionnaire asked the ADAP
administrators to provide medical eligibili-
ty standards for ADAP benefits in their
State during 1997, (responses summarized
in Table 2).  In addition to a diagnosis of
HIV infection, a number of States require a
CD4 count below a certain level (for exam-
ple, a CD4 count below 550 in Kentucky) or
a viral load above a certain level (for exam-
ple, a viral load of 30,000 copies or more in
Mississippi) to meet ADAP medical eligi-
bility criteria in their State. Many States
only require documented infection with
HIV.  The ADAP in Oregon responded that
its T-cell requirement for eligibility was
dropped.
Financial Eligibility Policies
The questionnaire asked the ADAP
administrators to provide the maximum
gross monthly income during 1997 to be
eligible for ADAP benefits for both an indi-
HEALTH CARE FINANCING REVIEW/Spring 1998/Volume 19, Number 3 5
2 Given the similarity of responses from most States, these data
are not reported in Table 2.
3 Given the similarity of responses from most States, these data
are not reported in Table 2.
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vidual in a one-person household and an
individual in a four-person household.  As
Table 2 shows, these 1997 financial eligibil-
ity requirements for ADAP coverage in
most States allow relatively high income
levels, especially when compared with
Medicaid income eligibility requirements.
In most States the ADAP income eligibility
levels are at least twice the Federal pover-
ty guidelines, with a number of States
allowing even more generous income lev-
els for eligibility.  The ADAP in North
Dakota reported no upper limit on income
during 1997.
Trends in Financial Eligibility 
The ADAP administrators were asked in
the survey to compare financial eligibility
criteria implemented in 1996 with those in
place during 1997.  Compared with 1996,
financial eligibility criteria for the ADAPs
in the majority of States remained the
same.  However, financial eligibility criteria
did change during 1997, compared with
1996, in a number of States, as Table 2
shows.  The questionnaire also asked the
ADAP administrators if they expected the
financial eligibility criteria implemented in
their State to become more restrictive dur-
ing 1998.  The financial eligibility require-
ments for ADAP benefits in all States are
expected to remain the same during 1998,
except in North Carolina, Oregon, Rhode
Island, and the State of Washington, where
these criteria are expected to become more
restrictive.4 In response to this question,
the State of Washington further explained
that “we are considering requiring enrollees
with income between 200 percent FPL
[Federal poverty level] and 370 percent FPL
to have primary insurance, and we will only
pay as a secondary payer.”  (The ADAP in
Missouri did not answer this question.)
WAITING LISTS
The questionnaire asked the ADAP
administrators if their State implemented a
waiting list for people waiting to receive
ADAP benefits during 1997.  As Table 3
documents, ADAPs in 12 States reported
the use of waiting lists for ADAP benefits in
1997.  In addition to these 12, the ADAP in
North Carolina responded that it “will be
instituting” a waiting list for program bene-
fits, and the ADAP in Virginia had imple-
mented a waiting list during February
1997, although no one was waiting for ben-
efits at the time of the 1997 survey.  In con-
trast, during 1995, ADAPs in only Alabama,
Arkansas, Delaware, Indiana, and South
Carolina reported the implementation of
waiting lists.  Oklahoma anticipated the
use of waiting lists in 1995, and Nevada
reported that the mechanics for a waiting
list were developed in 1995, although no
one was waiting for benefits at the time of
the 1995 study (Buchanan and Smith,
1996).
Table 3 presents the number of people
waiting for ADAP benefits in States report-
ing the implementation of waiting lists dur-
ing 1997.  The ADAP administrator in
Florida responded that 850 Floridians were
waiting for ADAP coverage in late 1997,
with more than 100 people waiting in
Alabama, Mississippi, and South Carolina.
As Table 3 also illustrates, the length of
wait can be long, as much as 6 months or
longer in Alabama, Mississippi, Montana,
and South Dakota.  The South Carolina
ADAP responded that “We get 100 new
cases reported in South Carolina each
month.  We get several 100 applications
[for the ADAP] each month.  Right now it
takes six weeks to get on the program.
That can change tomorrow, based on 
funding.”
4 Given the similarity of responses from most States, these data
are not reported in Table 2.
PRESCRIPTION DRUG 
FORMULARIES
The ADAP administrators were asked in
the survey to provide the number of med-
ications on the ADAP drug formulary in
their State during 1997.  As Table 4 pre-
sents, the number of drugs on these for-
mularies varies among the States, ranging
at the time of the survey from three drugs
(all protease inhibitors) in Louisiana to as
many as 207 medications in New York.
The questionnaire asked the ADAP admin-
istrators to explain how a new drug can be
added to the ADAP formulary in their
State, with their responses summarized in
Table 4.  The ADAPs in most States utilize
a review process administered by a coun-
cil, board, committee, or advisory group.
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Table 3
Waiting Lists for Benefits under AIDS Drug Assistance Programs (ADAPs), by State: 1997
If There is an ADAP Waiting List,
Is There a Waiting List of Estimate the Following for 1997
People for ADAP Eligibility Number of People Length of Time
State During 1997? on Waiting List on Waiting List
Alabama Yes 100+ 6 Months
Delaware Yes 50 60+ Days
District of Columbia No Response to the Survey — —
Florida 1Yes 850 4 Months
Georgia Yes 35 30 Days
Indiana Yes 54 60-90 Days
Iowa No Response to the Survey — —
Mississippi Yes 138 210 Days
Missouri 2Yes 19 30 Days
Montana Yes 10 6 Months
Nevada Yes 45 60-120 Days
New Hampshire 3Yes 0 30 Days
North Carolina (4) Not Known at This Time Not Known at This Time
Oklahoma No Response to the Survey — —
South Carolina Yes 150 5 6 Weeks
South Dakota Yes 15 6-9 Months
Virginia 6No NA NA
1 Just developing in certain counties, not statewide.
2 “We have two programs within ADAP - General Medications and Protease Inhibitors.  There is a waiting list for Protease Inhibitors.”  Since the 
program was filled in February 1997, the number on the waiting list has been less than 20.
3 Have had wait list.
4 “Will be instituting a waiting list.”
5 “We get 100 new cases reported in South Carolina each month.  We get several 100 applications each month. Right now it takes 6 weeks to get 
on the program.  That can change tomorrow, based on funding.”
6 At the time of the survey response (March 26, 1997), there was no waiting list; but there had been a waiting list in February 1997.
NOTES: All other States responded that they had not implemented a waiting list.  NA is not applicable.  HIV is human immunodeficiency disease.
SOURCE: Buchanan, R.J., Medical University of South Carolina, 1997.

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Changes in the Number of Drugs
The questionnaire asked the ADAP
administrators to compare the number of
drugs on the ADAP formulary in their
State during 1996 with the number of med-
ications on this formulary in 1997.  The
number of drugs increased in almost all
States during 1997, with decreases report-
ed in Montana and Vermont.5 In addition,
the number of drugs on the ADAP formu-
lary remained the same during 1997 in
Arkansas, Louisiana, Maryland, Nebraska,
North Dakota, Oregon, and Pennsylvania.
(The District of Columbia, Iowa, and
Oklahoma did not respond to the survey.)  
The ADAP administrators also were
asked if they expected the number of med-
ications on the ADAP formulary in their
State to change during 1998.  Almost all
ADAP administrators expected the num-
ber of drugs on the ADAP formulary in
their State to increase during 1998, includ-
ing South Carolina, which “hopes to add
drugs.”6 In contrast, the ADAP adminis-
trators in New Mexico and North Dakota
expected the number of drugs on their for-
mulary to decrease in 1998.  The number
of drugs on the ADAP formularies is
expected to remain the same during 1998
in Georgia, Nebraska, and South Dakota.
ADAP administrators in Pennsylvania and
Wyoming responded that at the time of the
survey they were unable to determine if
the number of drugs on their formularies
would change in 1998.  The administrators
in Louisiana, Michigan, and the State of
Washington responded that the number of
drugs on the formulary in their States dur-
ing 1998 depends on FDA approval of 
new medications.
Off-Label Use
A drug must be approved by the FDA as
safe and effective for uses described in a
New Drug Application before it can be
marketed (Lasagna, 1989).  Evidence of
safety and efficacy are provided by the
manufacturer from investigations of the
drug’s effects on controlled patient popula-
tions.  These investigations substantiate
the use of a drug for specific indications.
Although a drug may have multiple uses,
the FDA only approves labeling that
reflects indications for conditions that have
been researched within these trials (Laetz
and Silberman, 1991).
A physician, however, may prescribe a
drug approved by the FDA for other uses
besides those listed in the product label.  In
many circumstances the standard of care
for a particular condition may include a
drug not labeled for that use (Nightingale,
1986).  Prescribing a drug in this manner is
commonly called “off-label” or “unlabeled
use,” with this practice supported by such
organizations as the FDA, the American
Medical Association, and the American
Society of Hospital Pharmacists (Food and
Drug Administration, 1982; American
Society of Hospital Pharmacists, 1992).
The absence of an indication within the
product labeling, however, does not sug-
gest that off-label use is experimental or
inappropriate.
Many drugs used in the management of
HIV or in the treatment of associated
opportunistic infections are prescribed off
label (Buchanan and Smith, 1994).  In fact,
off-label use of medications in HIV disease
is often the community standard of prac-
tice for many HIV-related conditions
(Brosgart et al., 1996).  Recent FDA
actions increase the importance of allow-
ing off-label uses of drugs in HIV-related
16 HEALTH CARE FINANCING REVIEW/Spring 1998/Volume 19, Number 3
5 Given the similarity of responses from most States, these data
are not reported in Table 4.
6 Given the similarity of responses from most States, these data
are not reported in Table 4.
care.  In response to the spread of HIV
infection, the FDA changed its policies to
accelerate approval of drugs for serious
and life-threatening conditions, such as
HIV disease, allowing access earlier in the
approval process than previously permit-
ted (Dunbar, 1991; Edgar and Rothman,
1990).  Although these policy changes
expanded the number of medications avail-
able to treat HIV-related conditions, the
labeling of many of these drugs has been
approved with narrow indications, which
can limit patient access to these drugs if
ADAPs do not allow off-label use.  Another
reason for off-label use is that clinical
expertise in the rapidly evolving field of
AIDS-related care outdistances the regula-
tory process for approving new uses of
drug therapies.
The questionnaire asked the ADAP
administrators if the ADAP in their State
allowed the off-label use of drugs on the
ADAP formulary during 1997.  The ques-
tionnaire defined off-label use as “prescrib-
ing the drug for uses other than labeled
indications.”  As Table 4 shows, the ADAPs
in many States allowed the off-label use of
medications on the ADAP formulary dur-
ing 1997.  A number of ADAP administra-
tors also noted, however, that the off-label
use of drugs on the ADAP formulary was
not monitored in their State during 1997.  If
the ADAPs do not monitor or enforce pro-
hibitions on off-label use, then off-label use
of covered medications may occur.
PROTEASE INHIBITORS
Coverage of the Protease Inhibitors
The questionnaire concluded with a sec-
tion asking the ADAP administrators
about: (1) coverage of the protease
inhibitors, (2) which of these drugs were
covered, and (3) the impact that coverage
of these medications has had on the ADAP
in their State.  As Table 5 presents, almost
all the ADAPs covered the four protease
inhibitors approved by the FDA.  However,
the ADAPs in Nevada, Oregon, and South
Dakota did not cover any of the protease
inhibitors at the time of the survey.
Although the Arkansas ADAP did not
include protease inhibitors on its formula-
ry at the time of the survey, these medica-
tions were provided through the HIV con-
sortia funded by Title II of the CARE Act
according to the survey response from that
State.
Impact of the Protease Inhibitors
As Table 5 documents, coverage of pro-
tease inhibitors has had an impact on the
Title II programs in all but 9 of the 48 States
participating in the survey.  As Table 6 sum-
marizes, a shift in Title II funds from other
programs to the ADAPs is the most com-
mon impact reported (by 21 States), fol-
lowed by the implementation of waiting
lists in 7 States.  The “other” responses
reported in Table 6 were a cautiousness
and the development of a protocol for
adding new drugs in Connecticut, a shift of
State prevention funds in Illinois, studying
cost containment in Indiana, a temporary
limit on access to protease inhibitors in
Ohio, the use of Title II supplemental fund-
ing to add coverage of the protease
inhibitors in South Carolina, development
of guidelines for the specific use of protease
inhibitors in Tennessee, and increased
copayment responsibilities required from
patients in Utah.  (All of these responses
that are summarized as “other” in Table 6
are presented in detail in Table 5.)
SUMMARY AND CONCLUSIONS
The various programs funded at least in
part by Title II of the CARE Act strengthen
the public sector safety net that provides
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coverage of health and care-related ser-
vices to people with HIV disease.  These
CARE Act programs provide coverage to
people with HIV who lack private health
insurance or who do not qualify for
Medicaid or Medicare.  In this article, we
have focused on the ADAPs.  Financial eli-
gibility requirements for these ADAPs are
generous, allowing people with incomes
too high for Medicaid eligibility to qualify
for ADAP benefits.  The ADAP administra-
tors in almost all States expected these
financial eligibility criteria to remain the
same in their State during 1998.  At the
same time, the ADAP administrators in
almost all States expect the number of peo-
ple receiving ADAP benefits and the num-
ber of drugs on the ADAP formulary to
increase during 1998.  
Without increased public funding for the
ADAPs, the increasing number of people
receiving program benefits and the
increasing need for an expanding number
of beneficial medications will lead to some
form of rationing.  This rationing could be
more restrictive financial and medical eligi-
bility criteria, a reduction in the number of
covered drugs, limits on the number of
medications each beneficiary may receive,
the implementation of waiting lists, or
some combination of these or other
options.  As Tables 5 and 6 illustrate, these
forms of rationing are being implemented
by a number of States.  In addition, at least
12 States reported the implementation of
waiting lists for ADAP benefits during
1997, more than double the number of
States administering ADAP waiting lists in
1995.  The number of people on ADAP
waiting lists is increasing, along with the
number of days these people must wait for
prescription drug benefits to begin.
Increased public spending on the pro-
grams funded by the CARE Act is neces-
sary to provide the health services needed
by people with HIV disease and maintain
these important programs in the public
sector safety net for HIV care.
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Table 6
Impact of Protease Inhibitors on AIDS Drug Assistance Programs (ADAPs): 
Summary of Survey Responses
Impact Number of States Reporting Impact
A Shift of Funding From Other Title II Programs to the ADAP 21
No Impact/None Mentioned 9
Implementation of Waiting Lists for the ADAP 7
A Reduction in the Number of Medications on the ADAP Formulary 5
Planning to Impose Restrictions/ Impact Being Studied 5
Use of State Funds 5
Enrollment Capped 3
Longer Waits for People on the Waiting List for the ADAP 3
More Restrictive Financial Eligibility Standards for ADAP 3
More Restrictive Medical Eligibility Standards for the ADAP 3
Protease Inhibitors Not Covered at Time of Survey 3
A Cap/Limit on the Dollar Value of Medications Beneficiaries Receive 2
A Limit to the Number of Medications a Beneficiary May Receive 2
A Shift/Use of Title I Funds 2
More People on the Waiting List for the ADAP 2
Other 7
NOTE:  AIDS is acquired immunodeficiency syndrome.
SOURCE:  Buchanan, R.J., Medical University of South Carolina, 1997.
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